BLACK WEEKSFlaconcini −15% · kit −10% · resto −5%con il codiceSpedizione gratuita in Germania da 200 €

Questa pagina è stata tradotta automaticamente e può contenere errori. Sei madrelingua? Saremo felici di ricevere il tuo feedback e le tue correzioni.Invia feedback

The Peptide Desk The Peptide Desk
Dapagliflozin (Forxiga), foto del prodotto
Medication

Dapagliflozin (Forxiga)

Medication

  • Spedito dalla Germania

Ordine

Prezzo unitario - Spedizione gratuita in Germania da 200 € durante le Black Weeks
  • DHL con tracciamento
  • Imballaggio discreto

4.6 su 5 su Trustpilot73 recensioni

In sintesi

Dapagliflozin (Forxiga) in cifre

I dati chiave dalla nostra enciclopedia. Trascina il punto lungo la curva per vedere quanto resta dopo una dose, secondo il calcolo.

Voce completa dell'enciclopedia

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~12.9 hours

Half-life ~12.9 hours
After 26 hours: 25 %
Hour 1350 %Hour 24, next dose28 %Hour 2625 %Hour 3912.3 %Hour 653 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

about12.9hours

Class
SGLT2 inhibitorgliflozin, selective
Use
Oral1x daily
Sizes
10 mg1 size in the shop

Non esiste ancora un'analisi di laboratorio per Dapagliflozin (Forxiga). Vota a favoreFallo testare tu, noi paghiamo la metàTutte le analisi di laboratorio

Conoscenze

Tutto su Dapagliflozin (Forxiga)

FAQ

Domande frequenti

Fonti per ogni risposta: voce dell'enciclopedia

Hai ancora una domanda?

Scrivici, il nostro team ti aiuterà.

How does dapagliflozin work?

It blocks the transporter SGLT2 in the kidney, which brings filtered sugar back into the blood. The sugar then leaves with the urine without insulin being needed. Breakdown runs mainly via the enzyme UGT1A9 to an inactive metabolite.

Does it help without diabetes?

In the trials on heart failure and chronic kidney disease the effect was similar with and without diabetes. With reduced pumping the risk of worsening or cardiac death fell by 26 percent.

What did the kidney trial show?

Among 4,304 participants 9.2 percent on dapagliflozin and 14.5 percent on placebo had an event (halved kidney function, kidney failure or death). 19 had to be treated to prevent one. The trial was therefore stopped early.

What is euglycaemic ketoacidosis?

Acidosis from ketones with nearly normal blood sugar. Because sugar does not rise much, it was recognised late in a case series. The authors advise checking ketones in case of nausea, vomiting or malaise. In the large diabetes trial it occurred in 0.3 versus 0.1 percent.

Does it lower heart attacks and strokes?

Not clearly in the diabetes trial with 17,160 patients: 8.8 versus 9.4 percent major cardiovascular events. Hospital stays for heart failure and kidney events did fall clearly.

Which side effects are known?

Serious genital infections or those leading to a stop occurred in 0.9 versus 0.1 percent, ketoacidosis in 0.3 versus 0.1 percent. In the heart failure trials volume depletion, kidney problems and low blood sugar were not more common than on placebo.

Correlati

Prodotti correlati